Longevium Raises $7M for AI Longevity Lab at Dubai Science Park

What happened

UAE-based healthtech company Longevium has closed a $7 million seed round and announced plans to establish an AI-powered Longevity Research Laboratory at Dubai Science Park, with an expected opening in Q4 2026. The facility will be led by founder Dr Ksenia Butova and will operate as a research and development centre rather than a clinical services provider.

The laboratory's remit spans a broad range of emerging health technologies, including AI-driven digital twins, regenerative medicine, tissue engineering, advanced cell therapies, robotic diagnostics, smart medical devices, and noble gas therapies. A central focus will be developing tools capable of predicting health risks and measuring biological ageing — areas that sit at the intersection of data science and preventive medicine. The funding will be directed towards building out the facility and expanding research into next-generation diagnostics and clinical programmes.

The announcement aligns with Dubai's stated ambition to position itself as a global centre for longevity medicine, with Dubai Science Park serving as the institutional home for the venture.

Why it matters

Longevity medicine is rapidly shifting from a niche interest to a mainstream healthcare proposition, and with that shift comes an entirely new category of patient — or more precisely, health consumer. People engaging with longevity services are typically proactive, data-literate and highly engaged, which creates both an opportunity and a design challenge: how do you build experiences around deeply personal, emotionally loaded information such as biological age or predicted disease risk? The behavioural stakes are high. Research in health psychology consistently shows that how risk information is framed and delivered shapes whether people act on it constructively or disengage entirely.

For service designers and CX practitioners, the emergence of AI-powered diagnostics and digital twins introduces a new frontier of human-machine interaction in healthcare settings. The experience of receiving a personalised biological profile — generated by algorithms, interpreted by clinicians — demands careful attention to trust-building, transparency and emotional pacing. Getting the interface between data and human response wrong can undermine the very behaviour change these technologies are designed to support.

By the numbers

• $7 million raised in Longevium's first funding round
• Q4 2026 targeted opening date for the Dubai Science Park laboratory
• 7+ distinct research domains identified, spanning digital twins, robotic diagnostics, cell therapies and noble gas therapies

The Renascence take

Most commentary on longevity healthtech focuses on the science — the diagnostics, the biomarkers, the AI models. What tends to go unexamined is the experience architecture required to make any of it meaningful to an actual human being receiving the results.

Predicting biological age or flagging a future health risk is not, by itself, a service — it is raw information. The service begins the moment a person has to make sense of that information and decide what to do next. Longevity platforms that invest heavily in research capability but lightly in the emotional and behavioural design of how findings are communicated risk producing anxiety rather than agency. The most important design question here is not "how accurate is the model?" but "how does someone feel five minutes after receiving their result, and what do they do next?" Operators entering this space should treat the post-insight journey — the explanation, the framing, the follow-through — as the core product, not an afterthought.